Tevogen Bio

Update in progress

TVGN (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tevogen Bio Holdings Inc. is a clinical-stage immunotherapy company developing off-the-shelf, precision T cell therapies for infectious diseases, cancers and other disorders. TVGN 489 has completed Phase 1 for ambulatory high-risk COVID-19 and is in Phase 1 for acute SARS-CoV-2 with B-cell cancer immune suppression and Long COVID prevention. Preclinical programs include TVGN 920, TVGN 960, TVGN 601, TVGN 930 and TVGN 116. Formerly Tevogen Bio Inc., renamed Feb 2024. Based in Warren, NJ, founded 2020.

Company score

Sentiment: 0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive